Kuick Research Recently Published Report Highlights Clinical Development & Commercial Opportunities In Global Bispecific Antibodies Market
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:
-
Global Market Forecast Till 2029: > USD 36 Billion
-
Approved Bispecific Antibodies: 11
-
Yearly & Quarterly Sales Insight
-
Global & Regional Sales Insights
-
Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
-
Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
-
Fast Track Approval, Orphan Designation & Priority Status Insights
-
Approved Bispecific Antibodies Pricing & Dosage Analysis
-
Top 30 Companies Developing Bispecific Antibodies Competitive Insight
-
800 Pages Clinical & Commercial Opportunity insight
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market
Lutikizumab (ABT-981) represents an innovative advancement in the field of immunotherapy, serving as a novel human dual-variable domain immunoglobulin meticulously designed to bind and inhibit both IL-1α and IL-1β, while ensuring minimal interference with other members of the IL-1 family. Originating from Abbott Laboratories, the compound is now under the stewardship of AbbVie following acquisition, with the latter spearheading its continued development.
Currently undergoing phase 2 trials, lutikizumab emerges as a promising therapeutic candidate for addressing Hidradenitis suppurativa (HS), colloquially known as acne inversus, a distressing chronic inflammatory skin condition. Extensive research has revealed elevated levels of IL-1α and IL-1β in HS lesions, underscoring the rationale behind investigating lutikizumab's potential efficacy in mitigating this condition's symptoms.
In January 2024, AbbVie disclosed the eagerly awaited phase 2 trial results, which demonstrated notable achievements. Specifically, adults afflicted with moderate to severe HS, having previously experienced treatment failure with anti-TNF therapy, exhibited significantly higher response rates when administered lutikizumab (ABT-981) compared to placebo. The primary endpoint of achieving HS Clinical Response at week 16 was notably surpassed by those receiving lutikizumab, instilling optimism regarding its therapeutic potential in HS management.
Bolstered by these encouraging findings, AbbVie has resolved to progress lutikizumab's clinical program for HS into phase 3 trials, marking a significant stride towards addressing the unmet medical needs of individuals grappling with this challenging dermatological condition.